ARTICLE | Clinical News

M923: Ph III data

December 2, 2016 4:44 PM UTC

Top-line data from a double-blind, international Phase III trial in 516 patients with moderate to severe chronic plaque psoriasis showed that M923 met the primary endpoint of equivalence to Humira ada...

BCIQ Company Profiles

Momenta Pharmaceuticals Inc.